{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T06:08:43Z","timestamp":1790402923311,"version":"4.1.0"},"reference-count":132,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hum. Genet."],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s00439-025-02745-x","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T10:45:25Z","timestamp":1745232325000},"page":"481-503","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Advancing chronic myeloid leukemia research with next-generation sequencing: potential benefits, limitations, and future clinical integration"],"prefix":"10.1007","volume":"144","author":[{"given":"Henry","family":"Sutanto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laras","family":"Pratiwi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradana Zaky","family":"Romadhon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siprianus Ugroseno Yudho","family":"Bintoro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,21]]},"reference":[{"key":"2745_CR1","doi-asserted-by":"publisher","first-page":"4112","DOI":"10.3390\/cancers15164112","volume":"15","author":"E Abruzzese","year":"2023","unstructured":"Abruzzese E, Bocchia M, Trawinska MM, Raspadori D, Bondanini F, Sicuranza A, Pacelli P, Re F, Cavalleri A, Farina M et al (2023) Minimal residual disease detection at RNA and leukemic stem cell (LSC) levels: comparison of RT-qPCR, d-PCR and CD26+ stem cell measurements in chronic myeloid leukemia (CML) patients in deep molecular response (DMR). Cancers 15:4112. https:\/\/doi.org\/10.3390\/cancers15164112","journal-title":"Cancers"},{"key":"2745_CR2","doi-asserted-by":"publisher","first-page":"2064","DOI":"10.1080\/10428194.2021.1894652","volume":"62","author":"S Adnan-Awad","year":"2021","unstructured":"Adnan-Awad S, Kankainen M, Mustjoki S (2021) Mutational landscape of chronic myeloid leukemia: more than a single oncogene leukemia. Leuk Lymphoma 62:2064\u20132078. https:\/\/doi.org\/10.1080\/10428194.2021.1894652","journal-title":"Leuk Lymphoma"},{"key":"2745_CR3","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3390\/immuno5010006","volume":"5","author":"GJ Adytia","year":"2025","unstructured":"Adytia GJ, Sutanto H, Pratiwi L, Fetarayani D (2025) Advances in synthetic immunology for targeted treatment of systemic autoimmune diseases: opportunities, challenges, and future directions. Immuno 5:6. https:\/\/doi.org\/10.3390\/immuno5010006","journal-title":"Immuno"},{"key":"2745_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.69709\/CIConnect.2024.194763","volume":"1","author":"S Ahmed","year":"2024","unstructured":"Ahmed S (2024) Neoantigen-based cancer vaccines: current innovations, challenges, and future directions in personalized immunotherapy. CI Connect 1:1\u201310. https:\/\/doi.org\/10.69709\/CIConnect.2024.194763","journal-title":"CI Connect"},{"key":"2745_CR5","doi-asserted-by":"publisher","first-page":"10","DOI":"10.60087\/vol2iisue1.p21","volume":"2","author":"S Akter","year":"2024","unstructured":"Akter S (2024) AI-driven precision medicine: transforming personalized cancer treatment. JAPMI 2:10\u201321. https:\/\/doi.org\/10.60087\/vol2iisue1.p21","journal-title":"JAPMI"},{"key":"2745_CR6","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.jmoldx.2015.09.005","volume":"18","author":"M Alikian","year":"2016","unstructured":"Alikian M, Ellery P, Forbes M, Gerrard G, Kasperaviciute D, Sosinsky A, Mueller M, Whale AS, Milojkovic D, Apperley J et al (2016) Next-generation sequencing-assisted DNA-based digital PCR for a personalized approach to the detection and quantification of residual disease in chronic myeloid leukemia patients. J Mol Diagn 18:176\u2013189. https:\/\/doi.org\/10.1016\/j.jmoldx.2015.09.005","journal-title":"J Mol Diagn"},{"key":"2745_CR7","doi-asserted-by":"publisher","first-page":"4820","DOI":"10.3390\/cancers13194820","volume":"13","author":"R Alves","year":"2021","unstructured":"Alves R, Gon\u00e7alves AC, Rutella S, Almeida AM, De Las Rivas J, Trougakos IP, Sarmento Ribeiro AB (2021) Resistance to tyrosine kinase inhibitors in chronic myeloid leukemia\u2014from molecular mechanisms to clinical relevance. Cancers 13:4820. https:\/\/doi.org\/10.3390\/cancers13194820","journal-title":"Cancers"},{"key":"2745_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.11.025","author":"IH Ament","year":"2024","unstructured":"Ament IH, DeBruyne N, Wang F, Lin L (2024) Long-read RNA sequencing: a transformative technology for exploring transcriptome complexity in human diseases. Mol Ther. https:\/\/doi.org\/10.1016\/j.ymthe.2024.11.025","journal-title":"Mol Ther"},{"key":"2745_CR9","doi-asserted-by":"publisher","first-page":"1462697","DOI":"10.3389\/fimmu.2024.1462697","volume":"15","author":"M Amiri","year":"2024","unstructured":"Amiri M, Moaveni AK, Majidi Zolbin M, Shademan B, Nourazarian A (2024) Optimizing cancer treatment: the synergistic potential of CAR-T cell therapy and CRISPR\/Cas9. Front Immunol 15:1462697. https:\/\/doi.org\/10.3389\/fimmu.2024.1462697","journal-title":"Front Immunol"},{"key":"2745_CR10","doi-asserted-by":"publisher","first-page":"126","DOI":"10.48036\/apims.v20i2.842","volume":"20","author":"H Babar","year":"2024","unstructured":"Babar H, Malik HS, Umar M, Tasleem Z, Tahir N (2024) Prognostic and predictive implications of sokal scoring system in newly diagnosed chronic myeloid leukemia patients. Ann Pak Inst Med Sci 20:126\u2013130. https:\/\/doi.org\/10.48036\/apims.v20i2.842","journal-title":"Ann Pak Inst Med Sci"},{"key":"2745_CR11","doi-asserted-by":"publisher","first-page":"e944641","DOI":"10.12659\/AJCR.944641","volume":"25","author":"SM Bahashwan","year":"2024","unstructured":"Bahashwan SM (2024) Chronic myeloid leukemia with a rare philadelphia chromosome variant involving chromosome 16. Am J Case Rep 25:e944641. https:\/\/doi.org\/10.12659\/AJCR.944641","journal-title":"Am J Case Rep"},{"key":"2745_CR12","doi-asserted-by":"publisher","first-page":"e0192008","DOI":"10.1097\/01.HS9.0000974672.01920.08","volume":"7","author":"L Baraa","year":"2023","unstructured":"Baraa L, Nader S, Ines O, Boufrikha W, Laatiri A (2023) PB1964: comparison of clinico-hematological parameters and molecular and cytogenetic response of two BCR-ABL fusion transcripts in chronic myeloid leukemia treated with imatinib. HemaSphere 7:e0192008. https:\/\/doi.org\/10.1097\/01.HS9.0000974672.01920.08","journal-title":"HemaSphere"},{"key":"2745_CR13","doi-asserted-by":"publisher","first-page":"6141","DOI":"10.3390\/ijms20246141","volume":"20","author":"L Bavaro","year":"2019","unstructured":"Bavaro L, Martelli M, Cavo M, Soverini S (2019) Mechanisms of disease progression and resistance to tyrosine kinase inhibitor therapy in chronic myeloid leukemia: an update. IJMS 20:6141. https:\/\/doi.org\/10.3390\/ijms20246141","journal-title":"IJMS"},{"key":"2745_CR14","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.bulcan.2023.08.013","volume":"111","author":"A Bayle","year":"2024","unstructured":"Bayle A, Marino P, Baffert S, Margier J, Bonastre J (2024) Co\u00fbt des technologies de s\u00e9quen\u00e7age haut d\u00e9bit (NGS): revue de la litt\u00e9rature et enseignements. Bulletin du Cancer 111:190\u2013198. https:\/\/doi.org\/10.1016\/j.bulcan.2023.08.013","journal-title":"Bulletin du Cancer"},{"key":"2745_CR15","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41408-022-00742-1","volume":"12","author":"A Bidikian","year":"2022","unstructured":"Bidikian A, Kantarjian H, Jabbour E, Short NJ, Patel K, Ravandi F, Sasaki K, Issa GC (2022) Prognostic impact of ASXL1 mutations in chronic phase chronic myeloid leukemia. Blood Cancer J. 12:144. https:\/\/doi.org\/10.1038\/s41408-022-00742-1","journal-title":"Blood Cancer J."},{"key":"2745_CR16","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s10096-019-03520-3","volume":"38","author":"SA Boers","year":"2019","unstructured":"Boers SA, Jansen R, Hays JP (2019) Understanding and overcoming the pitfalls and biases of next-generation sequencing (NGS) methods for use in the routine clinical microbiological diagnostic laboratory. Eur J Clin Microbiol Infect Dis 38:1059\u20131070. https:\/\/doi.org\/10.1007\/s10096-019-03520-3","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2745_CR17","doi-asserted-by":"publisher","first-page":"93","DOI":"10.4103\/jpgm.JPGM_781_20","volume":"68","author":"K Bommannan","year":"2022","unstructured":"Bommannan K, Naseem S, Binota J, Varma N, Malhotra P, Varma S (2022) Tyrosine kinase domain mutations in chronic myelogenous leukemia patients: a single center experience. J Postgrad Med 68:93\u201397. https:\/\/doi.org\/10.4103\/jpgm.JPGM_781_20","journal-title":"J Postgrad Med"},{"key":"2745_CR18","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.3324\/haematol.2022.281493","volume":"107","author":"S Branford","year":"2022","unstructured":"Branford S, Apperley JF (2022) Measurable residual disease in chronic myeloid leukemia. Haematol 107:2794\u20132809. https:\/\/doi.org\/10.3324\/haematol.2022.281493","journal-title":"Haematol"},{"key":"2745_CR19","doi-asserted-by":"publisher","first-page":"e237335","DOI":"10.6004\/jnccn.2023.7335","volume":"22","author":"S Branford","year":"2024","unstructured":"Branford S, Fernandes A, Shahrin N, Maqsood M, Shanmuganathan N, Wadham C (2024) Beyond BCR::ABL1\u2014the role of genomic analyses in the management of CML. J Natl Compr Cancer Netw 22:e237335. https:\/\/doi.org\/10.6004\/jnccn.2023.7335","journal-title":"J Natl Compr Cancer Netw"},{"key":"2745_CR20","doi-asserted-by":"publisher","first-page":"5642","DOI":"10.1158\/1078-0432.CCR-16-0066","volume":"22","author":"DA Braun","year":"2016","unstructured":"Braun DA, Burke KP, Van Allen EM (2016) Genomic approaches to understanding response and resistance to immunotherapy. Clin Cancer Res 22:5642\u20135650. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0066","journal-title":"Clin Cancer Res"},{"key":"2745_CR21","doi-asserted-by":"publisher","first-page":"4030","DOI":"10.1182\/blood-2022-167600","volume":"140","author":"AL Brown","year":"2022","unstructured":"Brown AL, Homan C, Drazer MW, Yu K, Lawrence D, Feng J, Arriola-Martinez L, Pozsgai M, McNeely K, Ha T et al (2022) Somatic mutational landscape of hereditary hematopoietic malignancies associated with germline variants in RUNX1, GATA2 and DDX41. Blood 140:4030\u20134033. https:\/\/doi.org\/10.1182\/blood-2022-167600","journal-title":"Blood"},{"key":"2745_CR22","doi-asserted-by":"publisher","first-page":"9737","DOI":"10.3390\/cimb45120608","volume":"45","author":"S Cabello-Aguilar","year":"2023","unstructured":"Cabello-Aguilar S, Vendrell JA, Solassol J (2023) A Bioinformatics toolkit for next-generation sequencing in clinical oncology. CIMB 45:9737\u20139752. https:\/\/doi.org\/10.3390\/cimb45120608","journal-title":"CIMB"},{"key":"2745_CR23","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s44313-024-00010-0","volume":"59","author":"Y-U Cho","year":"2024","unstructured":"Cho Y-U (2024) The role of next-generation sequencing in hematologic malignancies. Blood Res. 59:11. https:\/\/doi.org\/10.1007\/s44313-024-00010-0","journal-title":"Blood Res."},{"key":"2745_CR24","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.3109\/10428194.2010.520774","volume":"51","author":"J-C Chomel","year":"2010","unstructured":"Chomel J-C, Sorel N, Bonnet M-L, Bertrand A, Brizard F, Roy L, Guilhot F, Turhan AG (2010) Extensive analysis of the T315I substitution and detection of additional ABL mutations in progenitors and primitive stem cell compartment in a patient with tyrosine kinase inhibitor-resistant chronic myeloid leukemia. Leuk Lymphoma 51:2103\u20132111. https:\/\/doi.org\/10.3109\/10428194.2010.520774","journal-title":"Leuk Lymphoma"},{"key":"2745_CR25","doi-asserted-by":"publisher","first-page":"81","DOI":"10.59854\/dhrrh.2024.2.2.81","volume":"2","author":"M Cirnu","year":"2024","unstructured":"Cirnu M, Marinescu D-C, Niculae C-F, Negru S-A, Ureche-Fotea A-A, Soare D-S, Bumbea H, Radu E (2024) Quantitative BCR::ABL1 Assay using digital real-time PCR system: clinical applications and insights. DHRHH 2:81\u201385. https:\/\/doi.org\/10.59854\/dhrrh.2024.2.2.81","journal-title":"DHRHH"},{"key":"2745_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2017\/3548936","volume":"2017","author":"M Crampe","year":"2017","unstructured":"Crampe M, Andrews C, Fortune A, Langabeer SE (2017) Late emergence of an Imatinib-resistant ABL1 kinase domain mutation in a patient with chronic myeloid leukemia. Case Rep Hematol 2017:1\u20133. https:\/\/doi.org\/10.1155\/2017\/3548936","journal-title":"Case Rep Hematol"},{"key":"2745_CR27","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1038\/s41375-023-02048-y","volume":"37","author":"NCP Cross","year":"2023","unstructured":"Cross NCP, Ernst T, Branford S, Cayuela J-M, Deininger M, Fabarius A, Kim DDH, Machova Polakova K, Radich JP, Hehlmann R et al (2023) European leukemianet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia. Leukemia 37:2150\u20132167. https:\/\/doi.org\/10.1038\/s41375-023-02048-y","journal-title":"Leukemia"},{"key":"2745_CR28","doi-asserted-by":"publisher","first-page":"10978","DOI":"10.18632\/oncotarget.23971","volume":"9","author":"C Cumbo","year":"2018","unstructured":"Cumbo C, Impera L, Minervini CF, Orsini P, Anelli L, Zagaria A, Coccaro N, Tota G, Minervini A, Casieri P et al (2018) Genomic BCR-ABL1 breakpoint characterization by a multi-strategy approach for \u201cpersonalized monitoring\u201d of residual disease in chronic myeloid leukemia patients. Oncotarget 9:10978\u201310986. https:\/\/doi.org\/10.18632\/oncotarget.23971","journal-title":"Oncotarget"},{"key":"2745_CR29","doi-asserted-by":"publisher","first-page":"S289","DOI":"10.1016\/S2152-2650(22)01367-2","volume":"22","author":"S De Santis","year":"2022","unstructured":"De Santis S, Monaldi C, Martelli M, Mancini M, Bruno S, Castagnetti F, Gugliotta G, Polakova KM, Ernst T, Maar D et al (2022) CML-184 a novel droplet digital PCR strategy for rapid and sensitive detection of BCR::ABL1 kinase domain mutations conferring resistance to second-generation tyrosine kinase inhibitors. Clin Lymphoma Myeloma Leuk 22:S289\u2013S290. https:\/\/doi.org\/10.1016\/S2152-2650(22)01367-2","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2745_CR30","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.6004\/jnccn.2020.0047","volume":"18","author":"MW Deininger","year":"2020","unstructured":"Deininger MW, Shah NP, Altman JK, Berman E, Bhatia R, Bhatnagar B, DeAngelo DJ, Gotlib J, Hobbs G, Maness L et al (2020) Chronic myeloid leukemia, version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 18:1385\u20131415. https:\/\/doi.org\/10.6004\/jnccn.2020.0047","journal-title":"J Natl Compr Cancer Netw"},{"key":"2745_CR31","doi-asserted-by":"publisher","first-page":"2828","DOI":"10.1182\/blood-2018-99-118219","volume":"132","author":"I Della Starza","year":"2018","unstructured":"Della Starza I, De Novi LA, Santoro A, Domenico S, Cavalli M, Soscia R, Paoloni F, Menale L, Apicella V, Ilari C et al (2018) Comparative analysis between RQ-PCR, digital-droplet-PCR and next-generation-sequencing (NGS) of Immunoglobulin\/T-cell receptor gene rearrangements to monitor minimal residual disease in adult acute lymphoblastic leukemia patients. Blood 132:2828\u20132828. https:\/\/doi.org\/10.1182\/blood-2018-99-118219","journal-title":"Blood"},{"key":"2745_CR32","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.3390\/biomedicines10092074","volume":"10","author":"S Dotolo","year":"2022","unstructured":"Dotolo S, Esposito Abate R, Roma C, Guido D, Preziosi A, Tropea B, Palluzzi F, Giac\u00f2 L, Normanno N (2022) Bioinformatics: from NGS data to biological complexity in variant detection and oncological clinical practice. Biomedicines 10:2074. https:\/\/doi.org\/10.3390\/biomedicines10092074","journal-title":"Biomedicines"},{"key":"2745_CR33","first-page":"385","volume-title":"Advanced intelligent systems for sustainable development (AI2SD\u20192019); advances in intelligent systems and computing Vol. 1103","author":"R Driouche","year":"2020","unstructured":"Driouche R (2020) Towards multi-approaches bioinformatics pipeline based on big data and cloud computing for next generation sequencing data analysis. In: Ezziyyani M (ed) Advanced intelligent systems for sustainable development (AI2SD\u20192019); advances in intelligent systems and computing Vol. 1103. Springer International Publishing, Cham, pp 385\u2013394 (ISBN 978-3-030-36663-6)"},{"key":"2745_CR34","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.leukres.2017.05.009","volume":"59","author":"M-H Duan","year":"2017","unstructured":"Duan M-H, Li H, Cai H (2017) A Rare E13a3 (B2a3) BCR-ABL1 fusion transcript with normal karyotype in chronic myeloid leukemia: the challenges in diagnosis and monitoring minimal residual disease (MRD). Leuk Res 59:8\u201311. https:\/\/doi.org\/10.1016\/j.leukres.2017.05.009","journal-title":"Leuk Res"},{"key":"2745_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1240115","author":"H Dutta","year":"2023","unstructured":"Dutta H, Jain N (2023) Post-translational modifications and their implications in cancer. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2023.1240115","journal-title":"Front Oncol"},{"key":"2745_CR36","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.leukres.2013.12.025","volume":"38","author":"MH Elias","year":"2014","unstructured":"Elias MH, Baba AA, Azlan H, Rosline H, Sim GA, Padmini M, Fadilah SAW, Ankathil R (2014) BCR-ABL kinase domain mutations, including 2 novel mutations in Imatinib resistant Malaysian chronic myeloid leukemia patients\u2014frequency and clinical outcome. Leuk Res 38:454\u2013459. https:\/\/doi.org\/10.1016\/j.leukres.2013.12.025","journal-title":"Leuk Res"},{"key":"2745_CR37","doi-asserted-by":"publisher","first-page":"155161","DOI":"10.1016\/j.prp.2024.155161","volume":"254","author":"M El-Tanani","year":"2024","unstructured":"El-Tanani M, Mishra V, Mishra Y, Hromi\u0107-Jahjefendi\u0107 A, Tambuwala MM (2024) The impact of the BCR-ABL Oncogene in the pathology and treatment of chronic myeloid leukemia. Pathol - Res Pract 254:155161. https:\/\/doi.org\/10.1016\/j.prp.2024.155161","journal-title":"Pathol - Res Pract"},{"key":"2745_CR38","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.hoc.2004.03.010","volume":"18","author":"S Faderl","year":"2004","unstructured":"Faderl S, Hochhaus A, Hughes T (2004) Monitoring of minimal residual disease in chronic myeloid leukemia. Hematol\/Oncol Clin N Am 18:657\u2013670. https:\/\/doi.org\/10.1016\/j.hoc.2004.03.010","journal-title":"Hematol\/Oncol Clin N Am"},{"key":"2745_CR39","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1182\/blood-2019-125614","volume":"134","author":"C Fava","year":"2019","unstructured":"Fava C, Berchialla P, Petiti J, Bochicchio MT, Izzo B, Giugliano E, Ottaviani E, Errichiello S, Rege Cambrin G, Venturi C et al (2019) A Comparison of droplet digital PCR and RT-qPCR for BCR-ABL1 monitoring in chronic myeloid leukemia. Blood 134:2092\u20132092. https:\/\/doi.org\/10.1182\/blood-2019-125614","journal-title":"Blood"},{"key":"2745_CR40","doi-asserted-by":"publisher","first-page":"620","DOI":"10.3390\/cancers14030620","volume":"14","author":"A Fernandes","year":"2022","unstructured":"Fernandes A, Shanmuganathan N, Branford S (2022) Genomic mechanisms influencing outcome in chronic myeloid leukemia. Cancers 14:620. https:\/\/doi.org\/10.3390\/cancers14030620","journal-title":"Cancers"},{"key":"2745_CR41","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jmoldx.2019.08.007","volume":"22","author":"G-N Franke","year":"2020","unstructured":"Franke G-N, Maier J, Wildenberger K, Cross M, Giles FJ, M\u00fcller MC, Hochhaus A, Niederwieser D, Lange T (2020) Comparison of real-time quantitative PCR and digital droplet PCR for BCR-ABL1 monitoring in patients with chronic myeloid leukemia. J Mol Diagn 22:81\u201389. https:\/\/doi.org\/10.1016\/j.jmoldx.2019.08.007","journal-title":"J Mol Diagn"},{"key":"2745_CR42","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.3390\/life12081135","volume":"12","author":"C Gaulin","year":"2022","unstructured":"Gaulin C, Kelemen K, Arana Yi C (2022) Molecular pathways in clonal hematopoiesis: from the acquisition of somatic mutations to transformation into hematologic neoplasm. Life 12:1135. https:\/\/doi.org\/10.3390\/life12081135","journal-title":"Life"},{"key":"2745_CR43","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13039-024-00698-w","volume":"17","author":"AA Gazola","year":"2024","unstructured":"Gazola AA, Lautert-Dutra W, Archangelo LF, Reis RBD, Squire JA (2024) Precision oncology platforms: practical strategies for genomic database utilization in cancer treatment. Mol Cytogenet 17:28. https:\/\/doi.org\/10.1186\/s13039-024-00698-w","journal-title":"Mol Cytogenet"},{"key":"2745_CR44","doi-asserted-by":"publisher","first-page":"4423","DOI":"10.1182\/blood.V104.11.4423.4423","volume":"104","author":"S Gupta","year":"2004","unstructured":"Gupta S, Berman E, Jhanwar S (2004) Results of conventional cytogenetics and interphase FISH (I-FISH) analyses in patients with a clinical and morphologic diagnosis of CML: analysis of 52 cases. Blood 104:4423\u20134423. https:\/\/doi.org\/10.1182\/blood.V104.11.4423.4423","journal-title":"Blood"},{"key":"2745_CR45","doi-asserted-by":"crossref","unstructured":"Hagar E, Hassan Hagar A 2022. Next-generation sequencing with emphasis on illumina and ion torrent platforms.","DOI":"10.14293\/S2199-1006.1.SOR-.PPA9N9O.v1"},{"key":"2745_CR46","unstructured":"Hameed M, Bilal M, Majid T, Majid A, Khan A 2023. Early risk prediction of chronic myeloid leukemia with protein sequences using machine learning-based meta-ensemble."},{"key":"2745_CR47","doi-asserted-by":"publisher","first-page":"6","DOI":"10.17656\/jsmc.10416","volume":"13","author":"M Hamid","year":"2023","unstructured":"Hamid M, Mohammed A, Mohamad D (2023) ASXL1 mutation analysis in chronic myeloid leukaemia patients. JSMC 13:6. https:\/\/doi.org\/10.17656\/jsmc.10416","journal-title":"JSMC"},{"key":"2745_CR48","doi-asserted-by":"publisher","first-page":"S293","DOI":"10.1016\/j.clml.2019.07.241","volume":"19","author":"P Harrington","year":"2019","unstructured":"Harrington P, Jackson S, Kizilors A, Lea N, Newman J, Gale R, Hassan S, Dimitriadou E, Cris\u00e0 E, Ficinksi L et al (2019) Clinical intervention using NGS-based kinase domain mutation testing in CML patients. Clin Lymphoma Myeloma Leuk 19:S293\u2013S294. https:\/\/doi.org\/10.1016\/j.clml.2019.07.241","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2745_CR49","doi-asserted-by":"crossref","unstructured":"H\u00f6ps W, Weiss M.M, Derks R, Galbany J.C, Den Ouden A, Van Den Heuvel S, Timmermans R, Smits J, Mokveld T, Dolzhenko E et al 2024. HiFi long-read genomes for difficult-to-detect clinically relevant variants.","DOI":"10.1101\/2024.09.17.24313798"},{"key":"2745_CR50","doi-asserted-by":"publisher","first-page":"5752","DOI":"10.3390\/cancers14235752","volume":"14","author":"S Hu","year":"2022","unstructured":"Hu S, Chen D, Xu X, Zhang L, Wang S, Jin K, Zheng Y, Zhu X, Jin J, Huang J (2022) Targeted next-generation sequencing identifies additional mutations other than BCR\u2237ABL in chronic myeloid leukemia patients: a chinese monocentric retrospective study. Cancers 14:5752. https:\/\/doi.org\/10.3390\/cancers14235752","journal-title":"Cancers"},{"key":"2745_CR51","doi-asserted-by":"publisher","first-page":"206","DOI":"10.60087\/jklst.vol3.n3.p.206-224","volume":"3","author":"D Huang","year":"2024","unstructured":"Huang D, Yang M, Wen X, Xia S, Yuan B (2024) AI-driven drug discovery: accelerating the development of novel therapeutics in biopharmaceuticals. J Knowl Learn Sci Technol 3:206\u2013224. https:\/\/doi.org\/10.60087\/jklst.vol3.n3.p.206-224","journal-title":"J Knowl Learn Sci Technol"},{"key":"2745_CR52","doi-asserted-by":"publisher","first-page":"153760","DOI":"10.1016\/j.prp.2022.153760","volume":"230","author":"BM Hussen","year":"2022","unstructured":"Hussen BM, Abdullah ST, Salihi A, Sabir DK, Sidiq KR, Rasul MF, Hidayat HJ, Ghafouri-Fard S, Taheri M, Jamali E (2022) The emerging roles of NGS in clinical oncology and personalized medicine. Pathol - Res Pract 230:153760. https:\/\/doi.org\/10.1016\/j.prp.2022.153760","journal-title":"Pathol - Res Pract"},{"key":"2745_CR53","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1186\/s12859-019-2791-8","volume":"20","author":"A Iacoangeli","year":"2019","unstructured":"Iacoangeli A, Al Khleifat A, Sproviero W, Shatunov A, Jones AR, Morgan SL, Pittman A, Dobson RJ, Newhouse SJ, Al-Chalabi A (2019) DNAscan: personal computer compatible NGS analysis, annotation and visualisation. BMC Bioinform 20:213. https:\/\/doi.org\/10.1186\/s12859-019-2791-8","journal-title":"BMC Bioinform"},{"key":"2745_CR54","doi-asserted-by":"publisher","first-page":"4839","DOI":"10.1182\/blood-2008-04-149948","volume":"112","author":"E Jabbour","year":"2008","unstructured":"Jabbour E, Kantarjian HM, Jones D, Reddy N, O\u2019Brien S, Garcia-Manero G, Burger J, Cortes J (2008) Characteristics and outcome of chronic myeloid leukemia patients with F317L BCR-ABL kinase domain mutation after therapy with tyrosine kinase inhibitors. Blood 112:4839\u20134842. https:\/\/doi.org\/10.1182\/blood-2008-04-149948","journal-title":"Blood"},{"key":"2745_CR55","doi-asserted-by":"publisher","first-page":"1976","DOI":"10.1101\/gr.279095.124","volume":"34","author":"A Jha","year":"2024","unstructured":"Jha A, Bohaczuk SC, Mao Y, Ranchalis J, Mallory BJ, Min AT, Hamm MO, Swanson E, Dubocanin D, Finkbeiner C et al (2024) DNA-m6A calling and integrated long-read epigenetic and genetic analysis with fibertools. Genome Res. 34:1976\u20131986. https:\/\/doi.org\/10.1101\/gr.279095.124","journal-title":"Genome Res."},{"key":"2745_CR56","doi-asserted-by":"publisher","DOI":"10.3329\/bjm.v35i20.73432","author":"A Kabir","year":"2024","unstructured":"Kabir A (2024) BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors. Bangla J Med. https:\/\/doi.org\/10.3329\/bjm.v35i20.73432","journal-title":"Bangla J Med"},{"key":"2745_CR57","doi-asserted-by":"publisher","first-page":"1200897","DOI":"10.3389\/fonc.2023.1200897","volume":"13","author":"M Kaehler","year":"2023","unstructured":"Kaehler M, Osteresch P, K\u00fcnstner A, Vieth SJ, Esser D, M\u00f6ller M, Busch H, Vater I, Spielmann M, Cascorbi I et al (2023) Clonal evolution in tyrosine kinase inhibitor-resistance: lessons from in vitro-models. Front Oncol 13:1200897. https:\/\/doi.org\/10.3389\/fonc.2023.1200897","journal-title":"Front Oncol"},{"key":"2745_CR58","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1080\/10428194.2020.1837366","volume":"62","author":"D Karigane","year":"2021","unstructured":"Karigane D, Kasahara H, Shiroshita K, Fujita S, Kobayashi H, Tamaki S, Yamazaki R, Yahagi K, Yatabe Y, Kondoh N et al (2021) Detection of residual disease in chronic myeloid leukemia utilizing genomic next generation sequencing reveals persistence of differentiated Ph+ B cells but not bone marrow stem\/progenitors. Leuk Lymphoma 62:679\u2013687. https:\/\/doi.org\/10.1080\/10428194.2020.1837366","journal-title":"Leuk Lymphoma"},{"key":"2745_CR59","doi-asserted-by":"publisher","DOI":"10.4274\/tjh.galenos.2024.2024.0280","author":"S Khan","year":"2024","unstructured":"Khan S, Sabar MF, Akbar M, Waris A (2024) Dilemma in diagnosis and management of CML in Pakistan. Tjh. https:\/\/doi.org\/10.4274\/tjh.galenos.2024.2024.0280","journal-title":"Tjh"},{"key":"2745_CR60","doi-asserted-by":"publisher","first-page":"47","DOI":"10.12717\/DR.2023.27.1.47","volume":"27","author":"N-K Kim","year":"2023","unstructured":"Kim N-K (2023) Normative Issues in next generation sequencing gene testing. Dev Reprod 27:47\u201356. https:\/\/doi.org\/10.12717\/DR.2023.27.1.47","journal-title":"Dev Reprod"},{"key":"2745_CR61","doi-asserted-by":"publisher","first-page":"101552","DOI":"10.1016\/j.beha.2024.101552","volume":"37","author":"HH Kreipe","year":"2024","unstructured":"Kreipe HH, Schlegelberger B (2024) Cytogenetics and genomics in CML and other myeloproliferative neoplasms. Best Pract Res Clin Haematol 37:101552. https:\/\/doi.org\/10.1016\/j.beha.2024.101552","journal-title":"Best Pract Res Clin Haematol"},{"key":"2745_CR62","doi-asserted-by":"publisher","DOI":"10.22376\/ijtos.2024.2.3.23-31","author":"P Krubaa","year":"2024","unstructured":"Krubaa P, Jha AM, Mahmood AAR, Kumar A, Abraham J (2024) Next-generation sequencing technology in cancer. Int J Tre Onc Sci. https:\/\/doi.org\/10.22376\/ijtos.2024.2.3.23-31","journal-title":"Int J Tre Onc Sci"},{"key":"2745_CR63","first-page":"19","volume":"1","author":"K Kucheria","year":"2003","unstructured":"Kucheria K, Talwar R (2003) Diagnosis and disease management in CML patients using conventional and molecular cytogenetics. Iranian J Biotechnol 1:19\u201325","journal-title":"Iranian J Biotechnol"},{"key":"2745_CR64","doi-asserted-by":"publisher","first-page":"975","DOI":"10.5306\/wjco.v15.i8.975","volume":"15","author":"P Kumar","year":"2024","unstructured":"Kumar P, Benjamin DJ, Darabi S, Kloecker G, Rezazadeh Kalebasty A (2024) Implications of genetic testing and informed consent before and after genetic testing in individuals with cancer. World J Clin Oncol 15:975\u2013981. https:\/\/doi.org\/10.5306\/wjco.v15.i8.975","journal-title":"World J Clin Oncol"},{"key":"2745_CR65","doi-asserted-by":"publisher","first-page":"e8616465","DOI":"10.1097\/01.HS9.0000969544.86164.65","volume":"7","author":"D Kustova","year":"2023","unstructured":"Kustova D, Kirienko A, Motyko E, Shuvaev V, Efremova E, Morozova E, Sidorkevich S, Martynkevich I (2023) P660: Next-generation sequencing (NGS) for detecting BCR::ABL-independent mutations in patients with chronic myeloid leukemia with resistance to tyrosine kinase inhibitor treatment. HemaSphere 7:e8616465. https:\/\/doi.org\/10.1097\/01.HS9.0000969544.86164.65","journal-title":"HemaSphere"},{"key":"2745_CR66","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/978-981-99-8401-5_4","volume-title":"Advances in bioinformatics","author":"N Le Bui","year":"2024","unstructured":"Le Bui N, Do V-Q, Chu D-T (2024) Bioinformatics in gene and genome analysis. In: Singh V, Kumar A (eds) Advances in bioinformatics. Springer Nature Singapore, Singapore, pp 97\u2013111 (ISBN 978-981-99-8400-8)"},{"key":"2745_CR67","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1186\/s12935-023-02938-2","volume":"23","author":"H Lee","year":"2023","unstructured":"Lee H, Seo J, Shin S, Lee S-T, Choi JR (2023) Development and validation of sensitive BCR::ABL1 fusion gene quantitation using next-generation sequencing. Cancer Cell Int 23:106. https:\/\/doi.org\/10.1186\/s12935-023-02938-2","journal-title":"Cancer Cell Int"},{"key":"2745_CR68","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1097\/JXX.0000000000000745","volume":"34","author":"M Levkova","year":"2022","unstructured":"Levkova M, Stoyanova M, Benkova-Petrova M, Georgieva M, Angelova L (2022) Variants of uncertain significance in the era of next-generation sequencing. J Am Assoc Nurse Pract 34:1018\u20131021. https:\/\/doi.org\/10.1097\/JXX.0000000000000745","journal-title":"J Am Assoc Nurse Pract"},{"key":"2745_CR69","doi-asserted-by":"publisher","first-page":"4207","DOI":"10.1182\/blood-2023-188208","volume":"142","author":"Z Li","year":"2023","unstructured":"Li Z, Peng D, Deng J, Xiong L, Yin P, Hu J, Qian C, Yao L, Yin H, Hong M et al (2023) Dynamic changes in ABL1 kinase domain mutations and comparative efficacy of third-generation tyrosine kinase inhibitors across different stages in acute lymphoblastic leukemia and chronic myeloid leukemia blast crisis patients. Blood 142:4207\u20134207. https:\/\/doi.org\/10.1182\/blood-2023-188208","journal-title":"Blood"},{"key":"2745_CR70","doi-asserted-by":"publisher","first-page":"1786","DOI":"10.1097\/01.HS9.0000850480.63416.32","volume":"6","author":"Z Ling","year":"2022","unstructured":"Ling Z, Xiaodong L, Xianwei W, Zhe Z, Linlin W, Yangwei L (2022) PB1907: clinical value of detecting ABL kinase mutations in chronic myeloid leukemia based on high throughput sequencing technology. HemaSphere 6:1786\u20131787. https:\/\/doi.org\/10.1097\/01.HS9.0000850480.63416.32","journal-title":"HemaSphere"},{"key":"2745_CR71","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1182\/blood-2020-140917","volume":"136","author":"H Liu","year":"2020","unstructured":"Liu H, Chen J, Wang F, Fang J, Teng W, Chen X, Zhang Y, Ma X, Cao P, Nie D et al (2020) NGS-based screening to comprehensively decipher TKIs resistant mutations in BCR-ABL1 positive leukemias. Blood 136:30\u201330. https:\/\/doi.org\/10.1182\/blood-2020-140917","journal-title":"Blood"},{"key":"2745_CR72","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/nrc.2017.125","volume":"18","author":"MR Luskin","year":"2018","unstructured":"Luskin MR, Murakami MA, Manalis SR, Weinstock DM (2018) Targeting minimal residual disease: a path to cure? Nat Rev Cancer 18:255\u2013263. https:\/\/doi.org\/10.1038\/nrc.2017.125","journal-title":"Nat Rev Cancer"},{"key":"2745_CR73","doi-asserted-by":"publisher","DOI":"10.14719\/tcb.3569","author":"P Mambatta Sankaranarayanan","year":"2024","unstructured":"Mambatta Sankaranarayanan P, Kanukollu S, Vangala AB, Vangala RK, Nair P (2024) A review of next-generation sequencing technologies and their impact on clinical research: assessing clinical efficacy and cost-effectiveness. Trends Curr Biol. https:\/\/doi.org\/10.14719\/tcb.3569","journal-title":"Trends Curr Biol"},{"key":"2745_CR74","doi-asserted-by":"publisher","first-page":"6753","DOI":"10.26355\/eurrev_201908_18566","volume":"23","author":"G Marceddu","year":"2019","unstructured":"Marceddu G, Dallavilla T, Guerri G, Manara E, Chiurazzi P, Bertelli M (2019) PipeMAGI: an integrated and validated workflow for analysis of NGS data for clinical diagnostics. Eur Rev Med Pharmacol Sci 23:6753\u20136765. https:\/\/doi.org\/10.26355\/eurrev_201908_18566","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2745_CR75","doi-asserted-by":"publisher","first-page":"108466","DOI":"10.1016\/j.mrrev.2023.108466","volume":"792","author":"F Marchetti","year":"2023","unstructured":"Marchetti F, Cardoso R, Chen CL, Douglas GR, Elloway J, Escobar PA, Harper T, Heflich RH, Kidd D, Lynch AM et al (2023) Error-corrected next generation sequencing \u2013 promises and challenges for genotoxicity and cancer risk assessment. Mutat Res - Rev Mutat Res 792:108466. https:\/\/doi.org\/10.1016\/j.mrrev.2023.108466","journal-title":"Mutat Res - Rev Mutat Res"},{"key":"2745_CR76","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/s41431-017-0081-3","volume":"26","author":"P Marino","year":"2018","unstructured":"Marino P, On behalf of NGSEco Group, Touzani R, Perrier L, Rouleau E, Kossi DS, Zhaomin Z, Charrier N, Goardon N, Preudhomme C et al (2018) Cost of cancer diagnosis using next-generation sequencing targeted gene panels in routine practice: a nationwide french study. Eur J Hum Genet 26:314\u2013323. https:\/\/doi.org\/10.1038\/s41431-017-0081-3","journal-title":"Eur J Hum Genet"},{"key":"2745_CR77","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1007\/s12185-010-0706-6","volume":"92","author":"Y Minami","year":"2010","unstructured":"Minami Y, Kajiguchi T, Abe A, Ohno T, Kiyoi H, Naoe T (2010) Expanded distribution of the T315I mutation among hematopoietic stem cells and progenitors in a chronic myeloid leukemia patient during imatinib treatment. Int J Hematol 92:664\u2013666. https:\/\/doi.org\/10.1007\/s12185-010-0706-6","journal-title":"Int J Hematol"},{"key":"2745_CR78","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1055\/s-0043-1771186","volume":"44","author":"DK Mishra","year":"2023","unstructured":"Mishra DK, Dey I, Demde R, Vinarkar S, Parihar M (2023) Disease response assessment modalities in chronic myeloid leukemia: past, present, and future. Indian J Med Paediatr Oncol 44:592\u2013601. https:\/\/doi.org\/10.1055\/s-0043-1771186","journal-title":"Indian J Med Paediatr Oncol"},{"key":"2745_CR79","doi-asserted-by":"publisher","first-page":"BMI22438","DOI":"10.4137\/BMI.S22438","volume":"10s3","author":"EV Morozova","year":"2015","unstructured":"Morozova EV, Vlasova YY, Pryanishnikova MV, Lepik KV, Afanasyev BV (2015) Efficacy of dasatinib in a CML patient in blast crisis with F317L mutation: a case report and literature review. Biomark Insights 10s3:BMI22438. https:\/\/doi.org\/10.4137\/BMI.S22438","journal-title":"Biomark Insights"},{"key":"2745_CR80","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1182\/blood.V116.21.1226.1226","volume":"116","author":"K Naqvi","year":"2010","unstructured":"Naqvi K, Kantarjian H, Quint\u00e1s-Cardama A, Jabbour E, O\u2019Brien S, Wierda WG, Borthakur G, Kadia T, Burton E, Cortes JE (2010) Characteristics and outcome of chronic myeloid leukemia (CML) patients with E255K and E255V BCR-ABL kinase domain mutations. Blood 116:1226\u20131226. https:\/\/doi.org\/10.1182\/blood.V116.21.1226.1226","journal-title":"Blood"},{"key":"2745_CR81","doi-asserted-by":"publisher","first-page":"5250","DOI":"10.1182\/blood-2011-05-349191","volume":"118","author":"T O\u2019Hare","year":"2011","unstructured":"O\u2019Hare T, Zabriskie MS, Eide CA, Agarwal A, Adrian LT, You H, Corbin AS, Yang F, Press RD, Rivera VM et al (2011) The BCR-ABL35INS insertion\/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Blood 118:5250\u20135254. https:\/\/doi.org\/10.1182\/blood-2011-05-349191","journal-title":"Blood"},{"key":"2745_CR82","doi-asserted-by":"publisher","first-page":"6361","DOI":"10.1182\/blood-2023-181162","volume":"142","author":"R Ovilla-Mart\u00ednez","year":"2023","unstructured":"Ovilla-Mart\u00ednez R, Baez Islas PE, Alaez-Verson C, Ramirez Muniz NE, Perez-Jacobo F, Barragan-Iba\u00f1ez G, Gonz\u00e1lez M, Lopez Valles JML, Banda-Garc\u00eda LI, Reynoso EE et al (2023) Getting to know the molecular landscape of R\/R chronic myeloid leukemia: NGS-based profiling of myeloid mutations beyond BCR\/ABL. Blood 142:6361\u20136361. https:\/\/doi.org\/10.1182\/blood-2023-181162","journal-title":"Blood"},{"key":"2745_CR83","doi-asserted-by":"publisher","first-page":"v444","DOI":"10.1093\/annonc\/mdz251.029","volume":"30","author":"H Park","year":"2019","unstructured":"Park H, Shin D-Y, Kim I, Sohn S-K, Koh Y, Lee J-H, Lee K-H, Kim D-Y, Kim H-J, Ahn J-S et al (2019) Use of droplet digital polymerase chain reaction for detecting minimal residual disease: a prospective Multi-Institutional Study. Annal Oncol 30:v444. https:\/\/doi.org\/10.1093\/annonc\/mdz251.029","journal-title":"Annal Oncol"},{"key":"2745_CR84","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.hoc.2017.04.007","volume":"31","author":"AB Patel","year":"2017","unstructured":"Patel AB, O\u2019Hare T, Deininger MW (2017) Mechanisms of resistance to ABL kinase inhibition in CML and the development of next generation ABL kinase inhibitors. Hematol Oncol Clin North Am 31:589\u2013612. https:\/\/doi.org\/10.1016\/j.hoc.2017.04.007","journal-title":"Hematol Oncol Clin North Am"},{"key":"2745_CR85","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1182\/bloodadvances.2023012127","volume":"8","author":"MA Perusini","year":"2024","unstructured":"Perusini MA, \u017d\u00e1\u010dkov\u00e1 D, Kim T, Pagnano K, Pavlovsky C, Je\u017e\u00ed\u0161kov\u00e1 I, Kvetkov\u00e1 A, Jur\u010dek T, Kim J, Yoo Y et al (2024) Mutations in myeloid transcription factors and activated signaling genes predict chronic myeloid leukemia outcomes. Blood Adv 8:2361\u20132372. https:\/\/doi.org\/10.1182\/bloodadvances.2023012127","journal-title":"Blood Adv"},{"key":"2745_CR86","doi-asserted-by":"publisher","first-page":"851","DOI":"10.3389\/fonc.2019.00851","volume":"9","author":"A Petrackova","year":"2019","unstructured":"Petrackova A, Vasinek M, Sedlarikova L, Dyskova T, Schneiderova P, Novosad T, Papajik T, Kriegova E (2019) Standardization of sequencing coverage depth in NGS: recommendation for detection of clonal and subclonal mutations in cancer diagnostics. Front Oncol 9:851. https:\/\/doi.org\/10.3389\/fonc.2019.00851","journal-title":"Front Oncol"},{"key":"2745_CR87","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1182\/blood-2020-138675","volume":"136","author":"L Pettersson","year":"2020","unstructured":"Pettersson L, Johansson Alm S, Almstedt A, Lazarevic V, Orrsj\u00f6 G, Shah-Barkhordar G, Fogelstrand L, Ehinger M (2020) DNA-based methods for measurable residual disease detection in NPM1 -mutated acute myeloid leukemia; establishment of cut-offs for qPCR, digital droplet PCR and targeted deep sequencing. Blood 136:6\u20136. https:\/\/doi.org\/10.1182\/blood-2020-138675","journal-title":"Blood"},{"issue":"Suppl 2","key":"2745_CR88","first-page":"66","volume":"60","author":"JP Radich","year":"2000","unstructured":"Radich JP (2000) The detection and significance of minimal residual disease in chronic myeloid leukemia. Medicina (B Aires) 60(Suppl 2):66\u201370","journal-title":"Medicina (B Aires)"},{"key":"2745_CR89","doi-asserted-by":"publisher","first-page":"147776","DOI":"10.1016\/j.gene.2023.147776","volume":"886","author":"A Rafiq Mohammed","year":"2023","unstructured":"Rafiq Mohammed A, Assad D, Rostami G, Hamid M (2023) Frequency and prognostic influence of ASXL1 mutations and its potential association with BCR-ABL1 transcript type and smoke in chronic myeloid leukemia patients. Gene 886:147776. https:\/\/doi.org\/10.1016\/j.gene.2023.147776","journal-title":"Gene"},{"key":"2745_CR90","unstructured":"Rahmani Z, Shahini N, Gat N, Yun Z, Jiang Y, Farchy O, Harel Y, Chaudhary V, Sharif M, Ayday E 2024. Privacy-preserving collaborative genomic research: a real-life deployment and vision."},{"key":"2745_CR91","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1182\/blood-2020-141345","volume":"136","author":"A Rio-Machin","year":"2020","unstructured":"Rio-Machin A, Casado-Izquierdo P, Miettinen J, Bewicke-Copley F, Khan N, Demeulemeester J, Krizs\u00e1n S, Zheng J, Middleton C, Yin W et al (2020) Integration of deep multi-omics profiling veals new insights into the biology of poor-risk acute myeloid leukemia. Blood 136:39\u201340. https:\/\/doi.org\/10.1182\/blood-2020-141345","journal-title":"Blood"},{"key":"2745_CR92","doi-asserted-by":"crossref","unstructured":"Sagniez M, Simpson S.M, Caron M, Rozendaal M, Par\u00e9 B, Sontag T, Langlois S, Rouette A, Lavall\u00e9e V.-P, Cellot S et al 2022. Real-time molecular classification of leukemias.","DOI":"10.1101\/2022.06.22.22276550"},{"key":"2745_CR93","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/nrg.2017.117","volume":"19","author":"JJ Salk","year":"2018","unstructured":"Salk JJ, Schmitt MW, Loeb LA (2018) Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutations. Nat Rev Genet 19:269\u2013285. https:\/\/doi.org\/10.1038\/nrg.2017.117","journal-title":"Nat Rev Genet"},{"key":"2745_CR94","doi-asserted-by":"publisher","first-page":"848","DOI":"10.3390\/biology13110848","volume":"13","author":"PHG Sanches","year":"2024","unstructured":"Sanches PHG, De Melo NC, Porcari AM, De Carvalho LM (2024) Integrating molecular perspectives: strategies for comprehensive multi-omics integrative data analysis and machine learning applications in transcriptomics, proteomics, and metabolomics. Biology 13:848. https:\/\/doi.org\/10.3390\/biology13110848","journal-title":"Biology"},{"key":"2745_CR95","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.clml.2021.04.014","volume":"21","author":"E Sant'Antonio","year":"2021","unstructured":"Sant'Antonio E, Camerini C, Rizzo V, Musolino C, Allegra A (2021) Genetic heterogeneity in chronic myeloid leukemia: how clonal hematopoiesis and clonal evolution may influence prognosis, treatment outcome, and risk of cardiovascular events. Clin Lymphoma Myeloma Leuk 21:573\u2013579. https:\/\/doi.org\/10.1016\/j.clml.2021.04.014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2745_CR96","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.clml.2023.03.004","volume":"23","author":"E Scalzulli","year":"2023","unstructured":"Scalzulli E, Carmosino I, Costa A, Bisegna ML, Martelli M, Breccia M (2023) Management of chronic myeloid leukemia patients in later lines: the role of ponatinib and new compounds. Clin Lymphoma Myeloma Leuk 23:420\u2013425. https:\/\/doi.org\/10.1016\/j.clml.2023.03.004","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2745_CR97","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1007\/s00432-021-03569-8","volume":"147","author":"V Sch\u00e4fer","year":"2021","unstructured":"Sch\u00e4fer V, White HE, Gerrard G, M\u00f6bius S, Saussele S, Franke G-N, Mahon F-X, Talmaci R, Colomer D, Soverini S et al (2021) Assessment of individual molecular response in chronic myeloid leukemia patients with atypical BCR-ABL1 fusion transcripts: recommendations by the EUTOS cooperative network. J Cancer Res Clin Oncol 147:3081\u20133089. https:\/\/doi.org\/10.1007\/s00432-021-03569-8","journal-title":"J Cancer Res Clin Oncol"},{"key":"2745_CR98","doi-asserted-by":"publisher","first-page":"10","DOI":"10.59298\/ROJPHM\/2024\/321013","volume":"3","author":"H.M Moses","year":"2024","unstructured":"School of Natural and Applied Sciences Kampala International University Uganda, Moses H.M (2024) The role of precision medicine in rare diseases. ROJPHM 3:10\u201313. https:\/\/doi.org\/10.59298\/ROJPHM\/2024\/321013","journal-title":"ROJPHM"},{"key":"2745_CR99","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41467-024-44771-9","volume":"15","author":"MT Scott","year":"2024","unstructured":"Scott MT, Liu W, Mitchell R, Clarke CJ, Kinstrie R, Warren F, Almasoudi H, Stevens T, Dunn K, Pritchard J et al (2024) Activating P53 abolishes self-renewal of quiescent leukaemic stem cells in residual CML disease. Nat Commun 15:651. https:\/\/doi.org\/10.1038\/s41467-024-44771-9","journal-title":"Nat Commun"},{"key":"2745_CR100","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1158\/1538-7445.AM2022-764","volume":"82","author":"M Sedova","year":"2022","unstructured":"Sedova M, Ongpin A, Burke J, Seeger C, Brozio S, Au-Young J, Huang J, Jayaweera T, Casuga I, Huynh M et al (2022) Abstract 764: fully automated sample-to-report NGS workflow for comprehensive genomic profiling for myeloid neoplasms. Cancer Res 82:764\u2013764. https:\/\/doi.org\/10.1158\/1538-7445.AM2022-764","journal-title":"Cancer Res"},{"key":"2745_CR101","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12943-022-01565-1","volume":"21","author":"SC Selvakumar","year":"2022","unstructured":"Selvakumar SC, Preethi KA, Ross K, Tusubira D, Khan MWA, Mani P, Rao TN, Sekar D (2022) CRISPR\/Cas9 and next generation sequencing in the personalized treatment of cancer. Mol Cancer 21:83. https:\/\/doi.org\/10.1186\/s12943-022-01565-1","journal-title":"Mol Cancer"},{"key":"2745_CR102","doi-asserted-by":"publisher","first-page":"43","DOI":"10.6004\/jnccn.2024.0007","volume":"22","author":"NP Shah","year":"2024","unstructured":"Shah NP, Bhatia R, Altman JK, Amaya M, Begna KH, Berman E, Chan O, Clements J, Collins RH, Curtin PT et al (2024) Chronic myeloid leukemia, version 2.2024, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 22:43\u201369. https:\/\/doi.org\/10.6004\/jnccn.2024.0007","journal-title":"J Natl Compr Cancer Netw"},{"key":"2745_CR103","doi-asserted-by":"crossref","unstructured":"Shahzad AR, Iqbal M, Amin MA, Bangyal WH, Shahzad A.R 2023. Machine learning driven dashboard for chronic myeloid leukemia prediction using protein sequences.","DOI":"10.20944\/preprints202312.0053.v1"},{"key":"2745_CR104","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1055\/s-0041-1732854","volume":"42","author":"O Shetty","year":"2021","unstructured":"Shetty O, Gurav M, Bapat P, Karnik N, Wagh G, Pai T, Epari S, Desai S (2021) Moving next-generation sequencing into the clinic. Indian J Med Paediatr Oncol 42:221\u2013228. https:\/\/doi.org\/10.1055\/s-0041-1732854","journal-title":"Indian J Med Paediatr Oncol"},{"key":"2745_CR105","doi-asserted-by":"publisher","first-page":"113329","DOI":"10.1016\/j.intimp.2024.113329","volume":"143","author":"R Shi","year":"2024","unstructured":"Shi R, Ran L, Tian Y, Guo W, Zhao L, Jin S, Cheng J, Zhang Z, Ma Y (2024) Prospects and challenges of neoantigen applications in oncology. Int Immunopharmacol 143:113329. https:\/\/doi.org\/10.1016\/j.intimp.2024.113329","journal-title":"Int Immunopharmacol"},{"key":"2745_CR106","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.leukres.2012.09.012","volume":"37","author":"L-Y Shih","year":"2013","unstructured":"Shih L-Y, Kuo M-C, Kuo C-Y, Lin T-H, Bai L-Y, Chen T-Y, Wang M-C, Lin T-L, Lan Y-J, Chen C-C et al (2013) Emerging kinetics of BCR\u2013ABL1 mutations and their effect on disease outcomes in chronic myeloid leukemia patients with imatinib failure. Leuk Res 37:43\u201349. https:\/\/doi.org\/10.1016\/j.leukres.2012.09.012","journal-title":"Leuk Res"},{"key":"2745_CR107","doi-asserted-by":"publisher","first-page":"91","DOI":"10.9734\/jsrr\/2024\/v30i112536","volume":"30","author":"LS Singh","year":"2024","unstructured":"Singh LS, Iqbal G, Singh A, Limbola M, Kumar AV (2024) The impact of next-generation sequencing on biotechnology: a review of current applications. J Sci Res Rep 30:91\u201397. https:\/\/doi.org\/10.9734\/jsrr\/2024\/v30i112536","journal-title":"J Sci Res Rep"},{"key":"2745_CR108","doi-asserted-by":"publisher","first-page":"e00210","DOI":"10.1016\/j.plabm.2021.e00210","volume":"25","author":"D Smitalova","year":"2021","unstructured":"Smitalova D, Dvorakova D, Racil Z, Romzova M (2021) Digital PCR can provide improved BCR-ABL1 detection in chronic myeloid leukemia patients in deep molecular response and sensitivity of standard quantitative methods using EAC assays. Pract Lab Med 25:e00210. https:\/\/doi.org\/10.1016\/j.plabm.2021.e00210","journal-title":"Pract Lab Med"},{"key":"2745_CR109","doi-asserted-by":"publisher","first-page":"RP87133","DOI":"10.7554\/eLife.87133","volume":"12","author":"M Soka\u010d","year":"2023","unstructured":"Soka\u010d M, Kj\u00e6r A, Dyrskj\u00f8t L, Haibe-Kains B, Jwl Aerts H, Birkbak NJ (2023) Spatial transformation of multi-omics data unlocks novel insights into cancer biology. Elife 12:RP87133. https:\/\/doi.org\/10.7554\/eLife.87133","journal-title":"Elife"},{"key":"2745_CR110","doi-asserted-by":"publisher","first-page":"45","DOI":"10.70106\/rmr.v4i2.25","volume":"4","author":"JL Solari Yokota","year":"2024","unstructured":"Solari Yokota JL (2024) Avanzando hacia la equidad sanitaria mediante la innovaci\u00f3n tecnol\u00f3gica. Revista M\u00e9dica Rebagliati 4:45\u201346. https:\/\/doi.org\/10.70106\/rmr.v4i2.25","journal-title":"Revista M\u00e9dica Rebagliati"},{"key":"2745_CR111","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1182\/blood-2023-185162","volume":"142","author":"H-W Song","year":"2023","unstructured":"Song H-W, Kim S-H, Do YR, Ki K-M, Kim SH, Song M-S, Shin S-S, Kim D-W (2023) Highly sensitive chip-based digital pcr platform for quantitative detection of BCR::ABL1 transcripts throughout CML treatment. Blood 142:1805\u20131805. https:\/\/doi.org\/10.1182\/blood-2023-185162","journal-title":"Blood"},{"key":"2745_CR112","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.5858\/arpa.2019-0476-RA","volume":"144","author":"JA SoRelle","year":"2020","unstructured":"SoRelle JA, Wachsmann M, Cantarel BL (2020) Assembling and validating bioinformatic pipelines for next-generation sequencing clinical assays. Arch Pathol Lab Med 144:1118\u20131130. https:\/\/doi.org\/10.5858\/arpa.2019-0476-RA","journal-title":"Arch Pathol Lab Med"},{"key":"2745_CR113","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1182\/hematology.2023000447","volume":"2023","author":"S Soverini","year":"2023","unstructured":"Soverini S (2023) Resistance mutations in CML and how we approach them. Hematology 2023:469\u2013475. https:\/\/doi.org\/10.1182\/hematology.2023000447","journal-title":"Hematology"},{"key":"2745_CR114","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.3390\/genes15111357","volume":"15","author":"Z Tang","year":"2024","unstructured":"Tang Z, Wang W, Toruner GA, Hu S, Fang H, Xu J, You MJ, Medeiros LJ, Khoury JD, Tang G (2024) Optical genome mapping for detection of BCR::ABL1\u2014another tool in our toolbox. Genes 15:1357. https:\/\/doi.org\/10.3390\/genes15111357","journal-title":"Genes"},{"key":"2745_CR115","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1007\/s12288-016-0755-y","volume":"33","author":"AK Tripathi","year":"2017","unstructured":"Tripathi AK, Verma SP, Kumar N (2017) Mutation analysis in chronic myeloid leukemia patient in chronic phase on Imatinib having delayed achievement of milestones or loss of response. Indian J Hematol Blood Transfus 33:316\u2013320. https:\/\/doi.org\/10.1007\/s12288-016-0755-y","journal-title":"Indian J Hematol Blood Transfus"},{"key":"2745_CR116","unstructured":"TRUPCR\u00ae BCR-ABL1 Transcript screening kit Available online: https:\/\/3bblackbio.com\/trupcr-bcr-abl1-transcript-screening-kit.html (Accessed on 18 March 2025)."},{"key":"2745_CR117","doi-asserted-by":"publisher","first-page":"936","DOI":"10.12669\/pjms.314.7261","volume":"31","author":"ID Ujjan","year":"1969","unstructured":"Ujjan ID, Akhund AA, Khan S, Qureshi MA, Khan S (1969) Cytogenetic and molecular analyses of philadelphia chromosome variants in CML (chronic myeloid leukemia) patients from sindh using karyotyping and RT-PCR. Pak J Med Sci 31:936. https:\/\/doi.org\/10.12669\/pjms.314.7261","journal-title":"Pak J Med Sci"},{"key":"2745_CR118","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1182\/blood-2002-02-0571","volume":"101","author":"M Uzunel","year":"2003","unstructured":"Uzunel M, Mattsson J, Brune M, Johansson J-E, Aschan J, Ringd\u00e9n O (2003) Kinetics of minimal residual disease and chimerism in patients with chronic myeloid leukemia after nonmyeloablative conditioning and allogeneic stem cell transplantation. Blood 101:469\u2013472. https:\/\/doi.org\/10.1182\/blood-2002-02-0571","journal-title":"Blood"},{"key":"2745_CR119","doi-asserted-by":"publisher","first-page":"12527","DOI":"10.3390\/cimb46110744","volume":"46","author":"V Vashisht","year":"2024","unstructured":"Vashisht V, Vashisht A, Mondal AK, Woodall J, Kolhe R (2024) From genomic exploration to personalized treatment: next-generation sequencing in oncology. CIMB 46:12527\u201312549. https:\/\/doi.org\/10.3390\/cimb46110744","journal-title":"CIMB"},{"key":"2745_CR120","doi-asserted-by":"publisher","first-page":"2898","DOI":"10.51891\/rease.v10i8.15346","volume":"10","author":"PHZ Viduedo","year":"2024","unstructured":"Viduedo PHZ, Candeia VCU, Martins VBL, Destefani AC, Destefani VC (2024) Harnessing the power of AI and machine learning for next-generation sequencing data analysis: a comprehensive review of applications, challenges, and future directions in precision oncology. Rease 10:2898\u20132904. https:\/\/doi.org\/10.51891\/rease.v10i8.15346","journal-title":"Rease"},{"key":"2745_CR121","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.csbj.2024.12.030","volume":"27","author":"Y Wu","year":"2025","unstructured":"Wu Y, Xie L (2025) AI-driven multi-omics integration for multi-scale predictive modeling of genotype-environment-phenotype relationships. Comput Struct Biotechnol J 27:265\u2013277. https:\/\/doi.org\/10.1016\/j.csbj.2024.12.030","journal-title":"Comput Struct Biotechnol J"},{"key":"2745_CR122","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s40364-024-00643-4","volume":"12","author":"X Wu","year":"2024","unstructured":"Wu X, Yang X, Dai Y, Zhao Z, Zhu J, Guo H, Yang R (2024) Single-cell sequencing to multi-omics: technologies and applications. Biomark Res 12:110. https:\/\/doi.org\/10.1186\/s40364-024-00643-4","journal-title":"Biomark Res"},{"key":"2745_CR123","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1389468","author":"D Xie","year":"2024","unstructured":"Xie D, An B, Yang M, Wang L, Guo M, Luo H, Huang S, Sun F (2024) Application and research progress of single cell sequencing technology in leukemia. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2024.1389468","journal-title":"Front Oncol"},{"key":"2745_CR124","doi-asserted-by":"publisher","first-page":"117568","DOI":"10.1016\/j.cca.2023.117568","volume":"551","author":"D Yadav","year":"2023","unstructured":"Yadav D, Patil-Takbhate B, Khandagale A, Bhawalkar J, Tripathy S, Khopkar-Kale P (2023) Next-generation sequencing transforming clinical practice and precision medicine. Clinica Chimica Acta 551:117568. https:\/\/doi.org\/10.1016\/j.cca.2023.117568","journal-title":"Clinica Chimica Acta"},{"key":"2745_CR125","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1093\/jalm\/jfae096","volume":"9","author":"Z Yan","year":"2024","unstructured":"Yan Z, Shi L, Li W, Liu W, Galderisi C, Spittle C, Li J (2024) A novel next-generation sequencing assay for the identification of BCR\u202f: ABL1 transcript type and accurate and sensitive detection of TKI-resistant mutations. J Appl Lab Med 9:886\u2013900. https:\/\/doi.org\/10.1093\/jalm\/jfae096","journal-title":"J Appl Lab Med"},{"key":"2745_CR126","doi-asserted-by":"publisher","first-page":"145","DOI":"10.14348\/molcells.2019.0252","volume":"43","author":"A Yokota","year":"2020","unstructured":"Yokota A, Huo L, Lan F, Wu J, Huang G (2020) The clinical, molecular, and mechanistic basis of RUNX1 mutations identified in hematological malignancies. Mol Cell 43:145\u2013152. https:\/\/doi.org\/10.14348\/molcells.2019.0252","journal-title":"Mol Cell"},{"key":"2745_CR127","doi-asserted-by":"publisher","first-page":"e15072","DOI":"10.1200\/JCO.2022.40.16_suppl.e15072","volume":"40","author":"S Yuan","year":"2022","unstructured":"Yuan S, Li R, Wang K, Shi X, Yu Y, Liu F, Wang A, Mei L, Chen H (2022) Systematic analysis of actionable gene fusions by NGS-based in pancancer for precision oncology in China. JCO 40:e15072\u2013e15072. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.e15072","journal-title":"JCO"},{"key":"2745_CR128","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1117\/12.2692190","volume-title":"In proceedings of the international conference on modern medicine and global health (ICMMGH 2023)","author":"Y Zhang","year":"2023","unstructured":"Zhang Y (2023) The single-cell rna sequencing technology and its application. In: Sukumaran S (ed) In proceedings of the international conference on modern medicine and global health (ICMMGH 2023). SPIE:Oxford, United Kingdom, p 31"},{"key":"2745_CR129","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.ajpath.2022.03.016","volume":"192","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Huang X, Yan Q, Lin Y, Liu E, Mi Y, Liang S, Wang H, Xu J, Ru K (2022) The diagnosis of chronic myeloid leukemia with deep adversarial learning. Am J Pathol 192:1083\u20131091. https:\/\/doi.org\/10.1016\/j.ajpath.2022.03.016","journal-title":"Am J Pathol"},{"key":"2745_CR130","doi-asserted-by":"publisher","first-page":"1435635","DOI":"10.3389\/fimmu.2024.1435635","volume":"15","author":"S Zhou","year":"2024","unstructured":"Zhou S, Yang Y, Jing Y, Zhu X (2024) Generating advanced CAR-based therapy for hematological malignancies in clinical practice: targets to cell sources to combinational strategies. Front Immunol 15:1435635. https:\/\/doi.org\/10.3389\/fimmu.2024.1435635","journal-title":"Front Immunol"},{"key":"2745_CR131","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1080\/15476286.2024.2425527","volume":"21","author":"L Zong","year":"2024","unstructured":"Zong L, Zhu Y, Jiang Y, Xia Y, Liu Q, Wang J, Gao S, Luo B, Yuan Y, Zhou J et al (2024) An optimized workflow of full-length transcriptome sequencing for accurate fusion transcript identification. RNA Biol 21:1199\u20131208. https:\/\/doi.org\/10.1080\/15476286.2024.2425527","journal-title":"RNA Biol"},{"key":"2745_CR132","unstructured":"\u672c\u6751\u9df9\u591a\u6717; \u65b0\u4e95\u5eb7\u7950; \u5409\u85e4\u5eb7\u592a; \u5712\u5ddd\u4f50\u7d75\u5b50; \u9234\u6728\u3055\u3084\u304b; \u718a\u8c37\u9686\u5fd7 Interferon-\u03b1\u304a\u3088\u3073ponatinib\u304c\u594f\u52b9\u3057\u305fT315I, F317L\u5909\u7570\u3092\u6709\u3059\u308b\u6162\u6027\u9aa8\u9ac4\u6027\u767d\u8840\u75c5 2019."}],"container-title":["Human Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00439-025-02745-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00439-025-02745-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00439-025-02745-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T05:06:25Z","timestamp":1745643985000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00439-025-02745-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,21]]},"references-count":132,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["2745"],"URL":"https:\/\/doi.org\/10.1007\/s00439-025-02745-x","relation":{},"ISSN":["0340-6717","1432-1203"],"issn-type":[{"value":"0340-6717","type":"print"},{"value":"1432-1203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,21]]},"assertion":[{"value":"22 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The author declares no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}